Trading Halt
Filed with ASX · · 2 pages · English
On 6ix: 6ix.com/news/trading-halt-97
Trading in the securities of Neuren Pharmaceuticals Limited (‘NEU’) will be halted at the request of NEU, pending the release of an announcement by NEU. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of: • the commencement of normal trading on Friday, 6 February 2026; or • the release of the announcement to the market. NEU’s request for a trading halt is
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Acadia provides update on EU regulatory submission
- Response to ASX Aware Letter
- DAYBUE net sales projected to reach approx US$700m in 2028
- FDA approves DAYBUE STIX (trofinetide), powder formulation
- Record DAYBUE net sales of US$101.1 million in Q3 2025
Later from Neuren Pharmaceuticals
- Neuren receives US FDA meeting feeback for HIE and PTHS
- First patient dosed in Neuren PMS Phase 3 trial
- Neuren to commence new on-market share buy-back program
- Pause in Trading
- Acadia reports DAYBUE net sales for 2025 and 2026 guidance
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals